Ruzurgi™ (amifampridine) – New orphan drug approval
May 6, 2019 - The FDA announced the approval of Jacobus’ Ruzurgi (amifampridine), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.
Download PDF
